Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy
Cancer Chemotherapy and Pharmacology, 06/30/09
Horita Y et al. - BV does not affect the plasma concentration of CPT-11 and its metabolites on FOLFIRI regimen.
Related Articles
Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II
Cancer Epidemiology, Biomarkers & Prevention, 10/28/09
Relevance Score: 72%
Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk
Cancer Causes and Control, 10/02/09
Relevance Score: 72%
P73 expression and its clinical significance in colorectal cancer
Colorectal Disease, 10/19/09
Relevance Score: 71%
trans-Fatty acid consumption and its association with distal colorectal cancer in the North Carolina Colon Cancer Study II
Cancer Causes and Control, 10/28/09
Relevance Score: 70%
Association of clinicopathological features with UbcH10 expression in colorectal cancer
Journal of Cancer Research & Clinical Oncology, 10/01/09
Relevance Score: 70%
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
Knockdown of peroxisome proliferator-activated receptor-beta induces less differentiation and enhances cell–fibronectin adhesion of colon cancer cells
Oncogene, 11/25/09
A blood-based biomarker panel for stratifying current risk for colorectal cancer
International Journal of Cancer, 11/25/09
iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells
Molecular Cancer, 11/24/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial
British Journal of Cancer, 11/29/09
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


